explore
Previous article:
Trump demands the U.S. pay no more for drugs than other countries … again
Next article: Longer MASH drug regimen improved liver, Akero study finds
Next article: Longer MASH drug regimen improved liver, Akero study finds
knowledge
leisure time
-
Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more
2025-08-23 08:57 -
$1 billion proposal to grow Boston, Massachusetts biotech
2025-08-23 08:03 -
'Revelatory' study finds a smoking impact that remains after quitting
2025-08-23 07:36 -
State of the Union pitch: Bigger Medicare drug price negotiations
2025-08-23 07:16 -
Private equity deals in Medicare Advantage declines
2025-08-23 07:10 -
Gilead acquiring CymaBay and its liver disease drug for $4.3 billion
2025-08-23 06:37